Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial-Reference-Cited by-同舟云学术

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial

Published:2009-12 Issue:6 Volume:158 Page:998-1004.e1
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Berger Jeffrey S.,Roe Matthew T.,Gibson C. Michael,Kilaru Rakhi,Green Cynthia L.,Melton Laura,Blankenship James D.,Metzger D. Christopher,Granger Christopher B.,Gretler Daniel D.,Grines Cindy L.,Huber Kurt,Zeymer Uwe,Buszman Pawel,Harrington Robert A.,Armstrong Paul W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference17 articles.

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients;Lancet,1994

2. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Antman;Circulation,2008

3. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology;Silber;Eur Heart J,2005

4. Time to treatment in primary percutaneous coronary intervention;Nallamothu;N Engl J Med,2007

5. Facilitated PCI in patients with ST-elevation myocardial infarction;Ellis;N Engl J Med,2008

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs;ACS Pharmacology & Translational Science;2023-02-20

2. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic;Pharmacology & Therapeutics;2019-11

3. Potential Therapeutic Applications of P2 Receptor Antagonists: From Bench to Clinical Trials;Current Drug Targets;2019-06-11

4. Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents;Expert Opinion on Investigational Drugs;2018-12-22

5. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis;EuroIntervention;2018-05